'No-reflow' phenomenon following percutaneous coronary intervention: An uncommon complication

Angiology

Volumn 51, Issue 3, 2000, Pages 247-252

  Safi, Arshad M ^a,b   Kwan, Tak W ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CASE REPORT; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY STENT; EARLY DIAGNOSIS; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; NO REFLOW PHENOMENON; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0034021463     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970005100309     Document Type: Article

References (10)

1. Kloner RA, Ganote CE, Jennings RB: The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54:1496-1508, 1974.
2. Abbo KM, Dooris M, Glazier S, et al: Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 75:778-782, 1995.
3. Piana RN, Paik GY, Moscucci M, et al: Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 89:2514-2518, 1994.
4. Weyrens FJ, Mooney J, Lesser J, et al: Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 75:849-850, 1995.
5. Przyklenk K, Kloner RA: "Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase + catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature and regional blood flow. Circ Res 64:86-96, 1989.
6. Mueller HS, Rao PS, Greenberg MA, et al: Systemic and transcardiac platelet activity in acute myocardial infarction in man: Resistance to prostacyclin. Circulation 72:1336-1345, 1985.
7. Kloner RA, Rude RE, Carlson N, et al: Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: Which comes first? Circulation 62:945-952, 1980.
8. Kloner RA: No reflow visited. Editorial comment. J Am Coll Cardiol 14:1814-1815, 1989.
9. The EPIC Investigators: Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptors in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994.
10. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizations. N Engl J Med 336:1689-1696, 1997.